vTv Therapeutics Q3 net loss widens to $6.7M; cash drops to $8.2M

vTv Therapeutics Inc.

Net loss of $6.7M ($0.08 per share) vs $4.3M ($0.05) in Q3 2022.
Cash and equivalents fell to $8.2M from $12.1M at Dec. 31, 2022.
R&D expenses were $2.8M, down from $3.1M YoY on lower cadisegliatin costs.
Appointed Dr. Thomas Strack as Chief Medical Officer on November 2, 2023.
Received $4.4M from Reneo for repurchase of Reneo common stock on Nov 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

vTv Therapeutics Inc. reported third quarter ended September 30, 2023 results: revenue $ —, net income $6.7 million, EPS $0.08 per basic share.

Period: third quarter ended September 30, 2023
Revenue: $ —
Net income: $6.7 million
EPS: $0.08 per basic share
Result: reported results

Exact text from the filing

Net loss attributable to vTv shareholders for the three months ended September 30, 2023, was $6.7 million or $0.08 per basic share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.